203 related articles for article (PubMed ID: 20198424)
1. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.
Yoshida N; Kamada K; Tomatsuri N; Suzuki T; Takagi T; Ichikawa H; Yoshikawa T
Dig Dis Sci; 2010 Dec; 55(12):3393-8. PubMed ID: 20198424
[TBL] [Abstract][Full Text] [Related]
2. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease.
Gweon TG; Park JH; Kim BW; Choi YK; Kim JS; Park SM; Kim CW; Kim HG; Chung JW;
Gut Liver; 2018 Jan; 12(1):46-50. PubMed ID: 29069891
[TBL] [Abstract][Full Text] [Related]
3. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.
Adachi K; Furuta K; Miwa H; Oshima T; Miki M; Komazawa Y; Iwakiri K; Furuta T; Koike T; Shimatani T; Kinoshita Y
Dig Dis Sci; 2012 Jun; 57(6):1609-17. PubMed ID: 22367114
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection.
Fujiwara S; Morita Y; Toyonaga T; Kawakami F; Itoh T; Yoshida M; Kutsumi H; Azuma T
J Gastroenterol; 2011 May; 46(5):595-602. PubMed ID: 21359522
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter, Randomized, Controlled Trial of Rebamipide Plus Lansoprazole for the Treatment of Postendoscopic Submucosal Dissection Ulcers.
Yan B; Lu Z; Ge Z; Liu S; Guo X; Tian D; Yang Y; Li X; Gong W; Liu Z; Liu M; Zhou B; Zhao K; Pan F; Yang J; Yang Y
Clin Transl Gastroenterol; 2019 Jan; 10(1):e00008. PubMed ID: 30702488
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Ikuma M; Shirai N; Watanabe H; Umemura K; Kimura M; Hishida A
Eur J Clin Pharmacol; 2009 Jul; 65(7):693-8. PubMed ID: 19259653
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Springer M; Atkinson S; North J; Raanan M
Paediatr Drugs; 2008; 10(4):255-63. PubMed ID: 18590344
[TBL] [Abstract][Full Text] [Related]
8. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study.
Kato T; Araki H; Onogi F; Ibuka T; Sugiyama A; Tomita E; Nagaki M; Moriwaki H
J Gastroenterol; 2010 Mar; 45(3):285-90. PubMed ID: 19957195
[TBL] [Abstract][Full Text] [Related]
10. Dexlansoprazole for the treatment of esophagitis and GERD.
Davies SL
Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
[TBL] [Abstract][Full Text] [Related]
11. [Rebamipide using in gastroesophageal reflux disease treatment].
Ivashkin VT; Trukhmanov AS; Gonik MI
Ter Arkh; 2020 May; 92(4):98-104. PubMed ID: 32598706
[TBL] [Abstract][Full Text] [Related]
12. Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Mine S; Iida T; Tabata T; Kishikawa H; Tanaka Y
J Gastroenterol Hepatol; 2005 Sep; 20(9):1365-70. PubMed ID: 16105122
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.
Takayama M; Matsui S; Kawasaki M; Asakuma Y; Sakurai T; Kashida H; Kudo M
World J Gastroenterol; 2013 Sep; 19(34):5706-12. PubMed ID: 24039365
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
[TBL] [Abstract][Full Text] [Related]
15. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Mee AS; Rowley JL
Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Tolia V; Ferry G; Gunasekaran T; Huang B; Keith R; Book L
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S308-18. PubMed ID: 12607791
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole: in the management of gastroesophageal reflux disease in children.
Scott LJ
Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106
[TBL] [Abstract][Full Text] [Related]
18. Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Kato M; Asaka M; Sugiyama T; Kudo M; Nishikawa K; Sukegawa M; Hokari K; Katagiri M; Sato F; Kagaya H; Takeda H
Dig Dis Sci; 1998 Sep; 43(9 Suppl):198S-202S. PubMed ID: 9753250
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A;
Aliment Pharmacol Ther; 2003 Feb; 17(3):333-41. PubMed ID: 12562445
[TBL] [Abstract][Full Text] [Related]
20. [Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients].
Jeong YJ; Lee DH; Choi TH; Hwang TJ; Lee BH; Nah JC; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Kim N; Jung HC; Song IS
Korean J Gastroenterol; 2010 Feb; 55(2):100-8. PubMed ID: 20168056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
